General Anesthesia Drug Market - Trends Forecast Till 2028

Market Overview

The global general anesthesia drug market is anticipated to reach USD 6.8 billion in 2021 growing at a CAGR of 5.2% during the forecasting period, 2021-2028. 

Anesthesia drugs also popularly known as anesthetics are used to induce a general loss of sensation in the body. It does so by suppressing the sensory stimulation through acting on the brain and PNS (peripheral nervous system). These drugs are classified into 3 major types 1. General anesthesia 2. Local anesthesia 3. Regional anesthesia. General anesthesia leads to a loss of consciousness whereas in the case of local anesthesia there is a loss of sensation in a particular area which is achieved by blocking the conduction in nerves. Anesthesia can be given intravenously or can also be snorted. Some common drugs used to produce anesthesia are Barbiturates, Benzodiazepines, Etomidate, etc.

With a recent surge in cancer patients and emergency, surgeries are some of the factors that have supported long-term expansion for the global general anesthesia drug industry. 

Key Findings

Global general anesthesia drug market is segmented into the route of administration, end-user, and geography.

Route of Administration segment is segmented into Intravenous and Inhalational.

End-User segment is segmented into Hospitals, Ambulatory Surgery Centres.

Geographically, the global general anesthesia drug market is sub-segmented into North America, Europe, Asia-Pacific, Middle East and Africa, and South America and insights are provided for each region and major countries within the regions

Competitive Landscape

Key players in the global general anesthesia drug market are Baxter International Inc. (US), Hikma Pharmaceuticals plc (UK), Pfizer Inc. (US), Piramal Enterprises Limited (India), AbbVie (US), Fresenius SE & Co. KGaA (Germany), Par Pharmaceutical (US), Teva Pharmaceuticals (Israel), Viatris/Mylan (US), Novartis AG (US), Abbott Laboratories (US), AstraZeneca plc (US), F.Hoffmann-La Roche (Switzerland), GlaxoSmithKline plc (UK), Gilead Sciences, Inc. (US), Bayer AG (Germany), Merck & Co., Inc. (Germany), Sanofi (France), Heritage Pharmaceuticals Inc. (US), Akorn (US), and Apotex (Canada) among others.

Reasons to Acquire

• Increase your understanding of the market for identifying the best and suitable strategies and decisions on the basis of sales or revenue fluctuations in terms of volume and value, distribution chain analysis, market trends, and factors
• Gain authentic and granular data access for the global general anesthesia drug market so as to understand the trends and the factors involved behind changing market situations
• Qualitative and quantitative data utilization to discover arrays of future growth from the market trends of leaders to market visionaries and then recognize the significant areas to compete in the future
• In-depth analysis of the changing trends of the market by visualizing the historic and forecast year growth patterns

Report Scope